Answers are grounded in this paper and cite their sources.
Pilot study shows FMISO PET predicts progression-free survival in advanced lung cancer, suggesting its potential as an early response tool.
F] fluoro-D-glucose accumulation, tumor cell proliferation markers, prealbumin levels, tumor PD-L1, and stromal CD4 expression. When exploratory partial metabolic response (PMR) criteria of a ≥ 20% or ≥ 10% decrease in FMISO SUV were applied, progression-free survival differed significantly between PMR and non-PMR groups, whereas overall survival did not differ significantly. FMISO PET may serve as an exploratory tool for assessing early treatment response to ICIs in patients with advanced NSCLC. However, further studies are required to validate these findings.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: